Compare D R Horton Inc (DHI) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs GSK plc — how do they compare? D R Horton Inc trades at $134.88 (market cap $37.99B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 2.4× D R Horton Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and GSK plc for 93 Days on average.
| DHI | GSK | |
|---|---|---|
Market Cap | $37.99B | $91.88B |
Volume | 2,974,460 | 7,730,529 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $61.18 |
52-Week Low | $132.53 | $43.24 |
Typical Hold Time | 46 Days | 93 Days |
Enterprise Value | $43.09B | $111.88B |
Dividend Yield | 1.33% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $135.82, up 1.91% with a bearish technical signal despite recent earnings beats. The stock faces headwinds from rising mortgage rates impacting the housing sector, with revenue declining to $34.25B in 2025 and net income margin compressing to 9.15%. Analyst consensus remains positive with a $156.57 price target, but technical indicators show resistance at $137 with support at $133.
The outlook is mixed with strong fundamentals and attractive valuation (P/E 12.95) offset by macroeconomic pressures on housing demand. Key risks include persistent high interest rates and housing market volatility, while institutional sentiment leans bullish with 47% buy ratings. The stock offers value for long-term investors but faces near-term sector headwinds.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
